Clinical trial
Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
NCT07677267 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- June 30, 2026
- Completion date
- November 30, 2026
- Enrollment
- 1,067 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.